Digestive Enzyme Blend For Leaky Gut Clinical Trial

Table of Contents

1. What Is a Digestive Enzyme Blend and Why Does It Matter for Leaky Gut?
2. Understanding Leaky Gut: The Intestinal Permeability Problem
3. The Clinical Trial Landscape: What Studies Are Currently Running?
4. Key Clinical Data: What the Numbers Actually Show
5. Which Enzymes Matter Most in a Digestive Enzyme Blend for Leaky Gut?
6. Digestive Enzyme Blend Benefits for Leaky Gut: What Science Supports
7. Digestive Enzyme Blend Dosage for Leaky Gut: Timing, Amount, and Form
8. Natural Digestive Enzyme Blend Options: Food, Tea, and Supplements
9. Best Digestive Enzyme Blend for Leaky Gut: How to Evaluate Products
10. Safety, Side Effects, and What Clinical Trials Tell Us About Risk
11. Frequently Asked Questions
12. The Bottom Line

What Is a Digestive Enzyme Blend and Why Does It Matter for Leaky Gut?

When gastroenterologists and nutrition researchers talk about a digestive enzyme blend for leaky gut, they are referring to formulated combinations of specialized proteins that accelerate the breakdown of food macromolecules — carbohydrates, proteins, and fats — in the gastrointestinal tract. Unlike single-enzyme products, a blend targets multiple substrates simultaneously, which is important because most meals contain a complex mixture of nutrients that require different enzymatic pathways to digest properly.

The connection between enzyme function and leaky gut is more direct than many people realize. When carbohydrates, proteins, or fats are not broken down efficiently before they reach the lower intestine, undigested particles can accumulate in the gut lumen, feed pathogenic bacteria, and contribute to fermentation, gas production, and inflammatory signaling. Over time, this environment is associated with increased intestinal permeability — commonly known as leaky gut — where tight junctions between intestinal epithelial cells begin to loosen, allowing bacterial fragments such as lipopolysaccharides (LPS) to enter systemic circulation.

A digestive enzyme blend and leaky gut relief are therefore connected not just symptomatically but mechanistically. By improving upstream digestion, enzyme blends may reduce the volume of fermentable material reaching the colon, lower microbial-driven inflammation, and support the mucosal environment in which tight junction proteins function.

This article focuses specifically on the clinical trial evidence for this connection — what has been studied, what the data shows, what trials are currently enrolling, and what an informed consumer or clinician needs to understand before recommending or selecting a digestive enzyme blend leaky gut supplement.

Support Your Gut System, Reduce Bloating and Feel Lighter Within Minutes.

Try our new organic debloat + digest drops risk free

Verdant Debloat + Digest Drops - Feel Lighter in Minutes

Shop Organic Debloat + Digest Drops

Understanding Leaky Gut: The Intestinal Permeability Problem

What Leaky Gut Actually Means Clinically

"Leaky gut" is a colloquial term for increased intestinal permeability, a measurable phenomenon involving compromised tight junction integrity in the intestinal epithelium. The tight junction proteins — occludin, claudins, and zonula occludens proteins — form a selectively permeable barrier. When this barrier is disrupted, larger molecules including bacterial endotoxins, dietary antigens, and microbial metabolites can translocate into the lamina propria and from there into systemic circulation.

This is not a fringe concept. Increased intestinal permeability has been documented in conditions including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), celiac disease, non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome. Researchers measure it using tools such as the lactulose-to-mannitol ratio, zonulin serum levels, and fluorescein isothiocyanate (FITC)-dextran assays.

What Causes Tight Junction Disruption?

Multiple factors contribute to increased intestinal permeability:

• Chronic psychological stress, which alters enteric nervous system signaling and increases corticotropin-releasing factor (CRF), a known permeability mediator
• Dysbiosis, meaning imbalanced gut microbiota composition, particularly loss of butyrate-producing bacteria that fuel colonocyte health
• Dietary factors, including excess alcohol, ultra-processed foods, gluten in susceptible individuals, and high-FODMAP diets in people with IBS
• Incomplete digestion of fermentable substrates, allowing large carbohydrate molecules to reach the colon intact, where fermentation produces gases and inflammatory short-chain fatty acid imbalances
• Medications, including non-steroidal anti-inflammatory drugs (NSAIDs) and some antibiotics

Where Digestive Enzymes Enter the Picture

A 2024 PMC review examining leaky gut and ingredients that may help treat it discussed barrier-supportive compounds including probiotics, polyphenols, and amino acids such as glutamine. While that review did not focus specifically on digestive enzymes, the mechanistic rationale for using a natural digestive enzyme blend leaky gut intervention is grounded in the same principle: reducing inflammatory load in the gut lumen by improving the completeness of digestion before fermentable residues reach the colon.

This is particularly relevant for FODMAPs — fermentable oligosaccharides, disaccharides, monosaccharides, and polyols — which are among the most studied drivers of IBS-related symptoms and, in susceptible individuals, may contribute to the inflammatory milieu associated with increased permeability.

The Clinical Trial Landscape: What Studies Are Currently Running?

This is where the evidence base for a digestive enzyme blend for leaky gut clinical trial becomes most concrete. Between 2024 and 2026, the number of registered and published clinical studies examining digestive enzyme blends for gastrointestinal symptom reduction has increased substantially. Here is a detailed breakdown of what is currently in the literature and in active trial registries.

Study 1: The FODMAP-Targeting Enzyme Blend — First Human Data (2025, PMC)

Published in PMC in 2025, this study represents what the authors themselves described as the first human data on a fructan-digesting agent used specifically to reduce IBS symptom burden. The study examined a FODMAP-targeting digestive enzyme blend, with fructan hydrolase as its primary active component, in participants with self-reported IBS-related symptoms.

This was a real-world evidence study rather than a randomized controlled trial, which is important context for interpreting the results. However, the symptom improvement rates reported were clinically meaningful:

• 78.0% of participants reported improved bloating and flatulence after four weeks of use (95% CI: 69.7% to 84.5%)
• 75.0% reported improvement in abdominal pain (95% CI: 61.2% to 85.1%)
• At follow-up assessment, 72% reported significant improvement in overall digestive symptoms on the IBS Subject's Global Assessment (IBS-SGA) scale
• No adverse outcomes were reported among participants

The authors explicitly called for a prospective randomized controlled trial to confirm these findings, recognizing that real-world evidence, while valuable, carries inherent limitations including self-selection bias and the absence of a placebo comparator.

Study 2: Acute Physiological Effects of a Digestive Enzyme Blend (2024, Frontiers in Nutrition)

A 2024 study published in Frontiers in Nutrition took a different and arguably more rigorous mechanistic approach to studying leaky gut with digestive enzyme blend interventions. Rather than relying on symptom self-reports, researchers used an ileostomy model — participants with existing ileostomies — to directly measure what happens to macromolecule breakdown in the small intestine following enzyme blend supplementation.

The findings were physiologically significant: the enzyme blend significantly increased monosaccharide levels in ileostomy samples collected four hours after consumption, indicating faster and more complete carbohydrate breakdown in the small intestine. This is important because it demonstrates that a digestive enzyme blend can measurably change the substrate composition reaching the colon — producing more completely digested monosaccharides that are absorbed before reaching fermentable substrate-sensitive colonic bacteria, rather than intact disaccharides or oligosaccharides that fuel gas production and potentially inflammatory processes.

This kind of mechanistic data supports the rationale for using a digestive enzyme blend extract leaky gut approach — by intervening at the enzymatic level, you change what the colon receives, which changes the microbial and inflammatory environment downstream.

Study 3: Phase 2 Randomized, Double-Blind, Placebo-Controlled, Crossover Trial (2025, NCT06949735)

This is arguably the most methodologically rigorous trial in the current pipeline. Registered and reporting in 2025, NCT06949735 is a randomized, double-blind, placebo-controlled, crossover study evaluating a delayed-release porcine-derived digestive enzyme blend for its effects on postprandial responses following a high-macronutrient meal.

Key trial characteristics:

• Design: Randomized, double-blind, placebo-controlled, crossover
• Target enrollment: 24 participants
• Intervention: Delayed-release porcine-derived enzyme blend
• Primary focus: Postprandial responses to high-macronutrient meals

The delayed-release formulation is clinically relevant. Standard enzyme supplements release their active components in the stomach, where the acidic environment can denature enzyme proteins before they reach the small intestine where they are needed. A delayed-release or enteric-coated formulation protects enzyme activity until the product reaches the duodenum and jejunum.

Study 4: Large-Scale Multicenter RCT — 300-Person Target (2026, NCT07465562)

Perhaps the most ambitious study in this space is a multicenter, randomized, controlled clinical trial targeting 300 adults with IBS-related bloating. This trial is investigating a combination of alpha-galactosidase, beta-galactosidase, and prolyl-endopeptidase — three enzymes targeting distinct FODMAP categories — for food-related abdominal bloating.

The scale of this trial — 300 participants across multiple centers — represents a significant step toward the kind of high-quality evidence that regulatory bodies and clinical guideline committees require before issuing formal recommendations. If completed with positive outcomes, this study could reshape how clinicians think about enzyme supplementation in IBS and related conditions.

Study 5: FODZYME FODMAP-Targeting Enzyme Blend Crossover Trial (2026, IFFGD-Listed)

The International Foundation for Gastrointestinal Disorders (IFFGD) lists a randomized, double-blind, placebo-controlled crossover study of a FODMAP-targeting digestive enzyme blend for self-reported bloating. This study is sponsored by Kiwi Biosciences (FODZYME), the manufacturer of the fructan hydrolase-centered blend that generated the 2025 PMC real-world data described earlier.

The crossover design means each participant receives both the active enzyme blend and the placebo in sequence, with each participant serving as their own control. This design is particularly well-suited to studying symptom-based outcomes in gastrointestinal conditions where inter-individual variability is high.

Study 6: Blend of Digestive Enzymes and Extracts for Bloating (2026, MedPath)

An additional 2026 trial listing on MedPath describes an active or recruiting study examining a blend of digestive enzymes and extracts for bloating in adults. This study is noteworthy because it incorporates extract components alongside enzyme proteins — a formulation approach that aligns with the growing interest in combining enzymatic digestion support with botanical compounds that have anti-inflammatory or barrier-supportive properties.

Support Your Gut System, Reduce Bloating and Feel Lighter Within Minutes.

Try our new organic debloat + digest drops risk free

Verdant Debloat + Digest Drops - Feel Lighter in Minutes

Shop Organic Debloat + Digest Drops

Key Clinical Data: What the Numbers Actually Show

For readers who want the data without extensive narrative context, here is a consolidated summary of the most important clinical numbers currently available for digestive enzyme blends in gastrointestinal symptom research.

Symptom Improvement Rates from the 2025 PMC FODMAP Enzyme Study

| Symptom | Improvement Rate | 95% Confidence Interval | |---|---|---| | Bloating and flatulence | 78.0% | 69.7% to 84.5% | | Abdominal pain | 75.0% | 61.2% to 85.1% | | Overall digestive symptoms (IBS-SGA) | 72.0% | Not separately reported | | Adverse outcomes | 0% | N/A |

These numbers deserve careful interpretation. A 78% improvement rate in bloating with a lower confidence interval bound of 69.7% is clinically meaningful — it suggests that a substantial majority of users, even accounting for statistical uncertainty, experienced symptom relief. The zero adverse outcome rate over four weeks is encouraging from a safety standpoint, though the real-world study design means we cannot fully separate enzyme effects from placebo effects, dietary changes, or natural symptom fluctuation.

Physiological Data from the 2024 Frontiers in Nutrition Study

The ileostomy-based study did not report symptom improvement rates. Instead, it reported statistically significant increases in monosaccharide recovery from ileostomy samples four hours post-consumption in participants taking the enzyme blend versus control. This represents objective, measurable evidence of enhanced small intestinal carbohydrate digestion — a mechanistic validation of what the symptom studies suggest is happening clinically.

Trial Scale and Design Quality Across Active Studies

| Trial | Design | Size | Phase | |---|---|---|---| | NCT06949735 (2025) | Randomized, DB, PC, crossover | 24 | Phase 2 | | NCT07465562 (2026) | Multicenter, randomized, controlled | 300 | Not specified | | IFFGD/FODZYME (2026) | Randomized, DB, PC, crossover | Not listed | Not specified | | MedPath enzyme+extract (2026) | Randomized, controlled | Not listed | Not specified |

The progression from a 24-person phase 2 trial to a 300-person multicenter RCT reflects the normal trajectory of clinical evidence development — early mechanistic and feasibility data informing larger confirmatory trials.

Which Enzymes Matter Most in a Digestive Enzyme Blend for Leaky Gut?

Not all digestive enzyme blends are formulated equally, and the specific enzymes included in a product determine what substrates it can act on. For individuals concerned about leaky gut, the most clinically relevant enzyme classes are those that target FODMAP substrates — carbohydrates associated with fermentation, gas production, and potentially inflammatory gut responses.

Fructan Hydrolase (Inulinase)

Fructan hydrolase, also called inulinase, breaks down fructans — chains of fructose molecules found abundantly in wheat, onions, garlic, leeks, and asparagus. Fructans are among the most common triggers of IBS symptoms and are a key FODMAP category. The enzyme blend in the 2025 PMC study used fructan hydrolase as its primary active component, and this is the enzyme in FODZYME's commercial formulation.

Because humans lack endogenous fructan hydrolase activity, fructans ingested without supplemental enzyme support pass through the small intestine intact and reach the colon, where they are fermented by bacteria. This fermentation produces hydrogen and methane gas — the same gases measured in hydrogen breath tests — and the inflammatory byproducts of this fermentation may contribute to tight junction disruption.

Alpha-Galactosidase

Alpha-galactosidase breaks down raffinose and stachyose, oligosaccharides found in legumes (beans, lentils, chickpeas), cruciferous vegetables, and certain grains. This enzyme is the active ingredient in commercial products like Beano and is one of the three enzymes being studied in the 2026 multicenter 300-person RCT.

Beta-Galactosidase (Lactase)

Beta-galactosidase, better known as lactase, breaks down lactose — the disaccharide in dairy products — into glucose and galactose. Lactose intolerance affects an estimated 65–70% of the global adult population to varying degrees, and lactose malabsorption is a well-established cause of bloating, gas, and loose stools. Including beta-galactosidase in a digestive enzyme blend leaky gut supplement is particularly relevant for individuals who consume dairy.

Prolyl-Endopeptidase (PEP)

Prolyl-endopeptidase is a protease that cleaves gluten peptides — specifically the proline-rich sequences that make gluten resistant to complete digestion by endogenous human proteases. PEP does not eliminate gluten completely and should not be used as a substitute for a gluten-free diet in celiac disease. However, in non-celiac gluten sensitivity (NCGS), supplemental PEP may reduce the immune and inflammatory response triggered by residual gluten exposure. PEP is included in the formulation being studied in the 2026 multicenter RCT alongside alpha-galactosidase and beta-galactosidase.

Amylases, Lipases, and Proteases

Broader digestive enzyme blends also include:

• Amylases (alpha-amylase, glucoamylase): Break down starch and complex carbohydrates into simpler sugars
• Lipase: Facilitates fat emulsification and absorption; deficiency is associated with steatorrhea, malnutrition, and potentially dysbiosis
• Proteases/peptidases: Break down dietary proteins into amino acids and small peptides; incomplete protein digestion allows intact peptides to reach the colon and may contribute to immune reactivity and permeability changes

The 2024 Frontiers in Nutrition study examined a broad-spectrum enzyme blend targeting multiple macronutrient classes, while the 2025 PMC study focused on a FODMAP-specific blend centered on fructan hydrolase. Both approaches have merit, and the right choice depends on an individual's primary symptom triggers.

Digestive Enzyme Blend Extract Formulations

An emerging category of products combines enzyme proteins with botanical extracts that have been studied for anti-inflammatory or gut-barrier-supportive properties — compounds such as ginger extract, turmeric/curcumin, artichoke extract, and peppermint oil. The 2026 MedPath trial examining a blend of digestive enzymes and extracts is studying this combined approach. The theoretical advantage is that while enzymes address the upstream digestion problem, botanical extracts may simultaneously support the mucosal environment in which tight junction integrity is maintained.

Digestive Enzyme Blend Benefits for Leaky Gut: What Science Supports

Here is an honest, evidence-graded summary of digestive enzyme blend benefits leaky gut research as it currently stands.

Benefit 1: Reduction in Bloating and Flatulence — Strong Signal, Needs RCT Confirmation

The 78.0% improvement rate in bloating and flatulence from the 2025 PMC study, combined with the mechanistic data from the 2024 Frontiers in Nutrition ileostomy study showing increased small intestinal carbohydrate breakdown, provides a convergent evidence signal for this benefit. The limitation is that the primary human symptom data comes from a real-world observational study without a placebo control.

Evidence grade: Moderate (real-world data + mechanistic support; awaiting RCT confirmation)

Benefit 2: Reduction in Abdominal Pain — Encouraging But Preliminary

The 75.0% improvement rate in abdominal pain (95% CI: 61.2%–85.1%) is notable. Abdominal pain in IBS is mechanistically linked to visceral hypersensitivity, which can be modulated by luminal distension from gas production. By reducing fermentable substrate delivery to the colon, enzyme blends may reduce distension-driven pain signals.

Evidence grade: Moderate (real-world data only; mechanistic rationale strong)

Benefit 3: Overall Digestive Symptom Improvement — Consistent Across Measures

The 72% reporting significant improvement on the IBS-SGA at follow-up, combined with the specific symptom data above, suggests broad digestive benefit rather than improvement in isolated symptoms. This is clinically relevant because IBS is a multi-symptom condition.

Evidence grade: Moderate (real-world data; no adverse events reported)

Benefit 4: Faster Macronutrient Breakdown — Mechanistically Demonstrated

The 2024 Frontiers in Nutrition study provided physiological evidence of faster carbohydrate breakdown in the small intestine. This is not a symptom outcome — it is a direct measurement of enzyme function in the human gastrointestinal tract. This mechanistic benefit directly supports the rationale for using a natural digestive enzyme blend leaky gut intervention.

Evidence grade: Strong for the specific mechanism (objective ileostomy data)

Benefit 5: Reduced Dependence on Strict Low-FODMAP Dietary Restriction

One important implication of FODMAP-targeting enzyme therapy is that it may allow individuals with IBS-related food sensitivities to consume high-FODMAP foods with less symptom burden. This is not a cure for IBS or leaky gut, but it represents a meaningful quality-of-life benefit for people who have eliminated entire food groups to manage symptoms. The 2026 FODZYME crossover trial will provide more definitive data on this specific outcome.

Evidence grade: Preliminary (case reports, real-world data; RCT ongoing)

What the Evidence Does NOT Yet Support

It is equally important to be clear about what the current evidence does not yet demonstrate:

• Direct repair of tight junctions by digestive enzyme blends has not been demonstrated in humans. The connection between enzyme supplementation and reduced intestinal permeability is mechanistically plausible but not yet proven in controlled human trials.
• Equivalence to a low-FODMAP diet for IBS management has not been established. Enzyme blends are more appropriately positioned as complementary tools or aids for dietary flexibility rather than dietary replacements.
• Long-term benefits beyond four weeks are not yet established from the current data. The 2025 PMC study measured outcomes at four weeks and at a single follow-up point.

Digestive Enzyme Blend Dosage for Leaky Gut: Timing, Amount, and Form

Digestive enzyme blend dosage leaky gut is one of the most frequently asked questions in this space, and the honest answer is that standardized dosing guidance across all enzyme types does not yet exist in clinical practice. Here is what the current evidence and clinical reasoning suggest.

Timing: With or Before Meals

Digestive enzymes must be present in the gastrointestinal tract when food arrives to be effective. The general clinical consensus is:

• Standard capsule/tablet formulations: Take at the beginning of a meal or with the first bite
• Powder formulations (such as FODZYME): Mix directly with food before eating, so the enzyme contacts the FODMAP substrate as early as possible
• Delayed-release/enteric-coated formulations: Follow manufacturer guidance; these are designed to release in the small intestine and may tolerate slightly different timing

The 2025 phase 2 trial (NCT06949735) specifically studies a delayed-release formulation, which suggests that the research community recognizes delivery timing as a critical variable in enzyme efficacy.

Dose: What Clinical Studies Used

The 2025 PMC FODMAP enzyme study does not publicly report the exact dose used in the real-world evidence cohort for the fructan hydrolase product, as this was a consumer product study. The 2024 Frontiers in Nutrition study used doses specified in the published protocol for the ileostomy trial but these are not directly translatable to consumer dosing recommendations.

For commercial FODMAP-targeting enzyme blends, manufacturer recommendations typically range from one to three servings per meal depending on FODMAP content of the meal. For broader digestive enzyme blends, dosing is typically expressed in enzyme activity units (for example, lipase units, amylase units, or protease units) rather than milligrams of protein.

Form Matters: Capsule, Powder, Tablet, and Tea

Different delivery forms have meaningfully different pharmacokinetics in the digestive tract:

• Enteric-coated capsules: Protect enzymes from stomach acid; release in the small intestine; best for acid-sensitive enzymes like lipase
• Regular capsules: Release in the stomach; appropriate for enzymes with some acid stability; typically least expensive
• Powder (mixed with food): Allows enzyme to contact substrate before swallowing; potentially advantageous for FODMAP-targeting blends acting on food before ingestion begins
• Chewable tablets: Similar profile to regular capsules but may begin releasing in the mouth
• Digestive enzyme blend tea leaky gut products: Herbal teas that include enzyme-containing botanical ingredients such as papaya (papain), pineapple (bromelain), ginger, or licorice root. These typically provide lower enzyme concentrations than encapsulated supplements and serve more as digestive-supportive tonics than therapeutic-dose enzyme delivery vehicles. They may be appropriate as part of a broader wellness approach but should not be expected to provide the enzyme concentrations studied in clinical trials.

Frequency and Duration

Based on the 2025 PMC study's four-week assessment period and the ongoing trials with four-to-twelve-week durations, it appears that:

• Symptomatic benefits may appear within days to two weeks for bloating and gas related to FODMAP fermentation
• Four weeks appears to be the minimum duration for meaningful symptom assessment in clinical studies
• Long-term daily use for IBS symptom management appears to be the intended use pattern, rather than short-term treatment courses

Natural Digestive Enzyme Blend Options: Food, Tea, and Supplements

For individuals who prefer to start with food-based sources or want to understand how commercial natural digestive enzyme blend leaky gut products compare to whole foods, here is an overview of naturally occurring enzymes and their limitations relative to concentrated supplement formulations.

Food Sources of Digestive Enzymes

Several whole foods contain naturally occurring digestive enzymes in meaningful concentrations:

• Pineapple: Contains bromelain, a cysteine protease complex that breaks down proteins. Raw pineapple or pineapple juice provides active bromelain; cooking denatures it.
• Papaya: Contains papain, another plant protease with broad protein-degrading activity. Most effective when consumed raw.
• Mango: Contains amylases that increase in concentration as the fruit ripens, pre-digesting starches into simpler sugars.
• Honey (raw): Contains diastase (amylase), invertase, and small amounts of proteases. Heat processing destroys these enzymes.
• Fermented foods: Sauerkraut, kimchi, miso, kefir, and kombucha contain living organisms that produce enzymes during fermentation and may continue producing them in the gut. These overlap with the probiotic category.
• Ginger: Contains zingibain, a protease, and has demonstrated prokinetic effects — accelerating gastric emptying — which complements enzyme activity.

Digestive Enzyme Blend Tea for Leaky Gut Support

Digestive enzyme blend tea leaky gut formulations typically combine herbs associated with digestive support rather than concentrated enzyme proteins. Common ingredients include:

• Ginger root: Prokinetic, anti-nausea, mildly anti-inflammatory
• Peppermint: Antispasmodic for intestinal smooth muscle; well-supported by evidence for IBS symptom relief
• Licorice root (DGL): Deglycyrrhizinated licorice has mucosal protective properties and may support tight junction integrity
• Chamomile: Mild anti-inflammatory and spasmolytic properties
• Fennel: Carminative; reduces gas and bloating through relaxation of intestinal smooth muscle
• Papaya leaf: May contain residual papain activity

Herbal teas with these ingredients can provide meaningful symptomatic support for digestive discomfort and may complement a digestive enzyme supplement program. However, the enzyme concentrations in teas are generally too low and too poorly characterized to replicate the effects measured in clinical trials. Consider them supportive adjuncts rather than primary interventions.

Commercial Natural Enzyme Blend Supplements

Commercial natural digestive enzyme blends typically derive their enzymes from three sources:

1. Plant-derived: Bromelain (pineapple), papain (papaya), actinidin (kiwi), ficin (fig). Stable across a wider pH range than animal-derived enzymes.
2. Fungal-derived: Aspergillus-derived amylase, protease, and lipase. Very broad pH stability; effective across stomach acid and intestinal environments.
3. Animal-derived: Porcine or bovine pancreatin, containing a naturally occurring blend of amylase, protease, and lipase. Most closely mimics human pancreatic output; the formulation in NCT06949735 is porcine-derived.

The 2026 trial examining a blend of digestive enzymes and extracts (MedPath listing) suggests growing clinical interest in combining plant-derived enzyme components with botanical extracts that have barrier-supportive properties — a category that bridges the natural/pharmaceutical divide.

Support Your Gut System, Reduce Bloating and Feel Lighter Within Minutes.

Try our new organic debloat + digest drops risk free

Verdant Debloat + Digest Drops - Feel Lighter in Minutes

Shop Organic Debloat + Digest Drops

Best Digestive Enzyme Blend for Leaky Gut: How to Evaluate Products

Determining the best digestive enzyme blend for leaky gut depends on an individual's specific symptom profile, dietary patterns, and the evidence base supporting specific enzyme classes. Here is a framework for evaluation.

Step 1: Identify Your Primary Symptom Triggers

Different enzyme classes target different substrates. Before selecting a product, consider:

• Bloating and gas after eating beans, garlic, onion, or wheat? → Prioritize alpha-galactosidase and/or fructan hydrolase
• Symptoms specifically after dairy consumption? → Prioritize lactase (beta-galactosidase)
• Symptoms after meals high in starch? → Prioritize amylases
• Fat malabsorption symptoms (greasy stools, floating stools)? → Prioritize lipase, and consult a physician to rule out pancreatic insufficiency
• Broad post-meal discomfort without clear triggers? → Consider a full-spectrum blend with multiple enzyme classes

Step 2: Evaluate Enzyme Activity Units, Not Just Weight

The potency of a digestive enzyme supplement is measured in enzyme activity units, not milligrams of protein. Look for products that declare activity units using recognized standards:

• Lipase: LU (lipase units) or FIP units
• Amylase: DU (diastatic units) or SKB units
• Protease: HUT (hemoglobin units on tyrosine basis) or PC (papain units)
• Lactase: ALU (acid lactase units) or FCC lactase units
• Alpha-galactosidase: GaIU (galactosidase units)

Products that list only milligrams of enzyme powder without activity units provide insufficient information to assess potency.

Step 3: Evaluate Delivery Formulation

As discussed in the dosage section, delivery formulation affects where and how quickly enzymes are released in the GI tract. For individuals with significant gut inflammation or permeability concerns, an enteric-coated or delayed-release formulation may be preferable to ensure enzyme activity reaches the small intestine intact.

Step 4: Look for Third-Party Testing and GMP Certification

Since digestive enzyme supplements are regulated as dietary supplements in the United States rather than as drugs, manufacturers are not required to demonstrate efficacy or safety before selling. Look for:

• NSF International certification or USP verification (independent testing for label accuracy and purity)
• GMP (Good Manufacturing Practice) certification from the FDA or equivalent regulatory body
• Certificate of Analysis (CoA) available upon request, confirming enzyme activity potency matches label claims

Step 5: Consider Whether the Product Has Published Clinical Evidence

The most important distinguishing factor between a consumer wellness product and a clinically supported intervention is the existence of published research. The products being studied in the 2025 and 2026 trials — particularly the FODZYME fructan hydrolase blend — have more published human data than most commercial alternatives.

Step 6: Consult a Healthcare Provider for Complex Cases

If leaky gut symptoms are severe, persistent, or associated with autoimmune conditions, inflammatory bowel disease, or documented intestinal permeability on laboratory testing, enzyme supplementation should be part of a comprehensive clinical plan rather than a standalone intervention. A gastroenterologist, registered dietitian specializing in gut health, or functional medicine practitioner can help integrate enzyme therapy with dietary modification, probiotic therapy, and other evidence-based interventions.

Safety, Side Effects, and What Clinical Trials Tell Us About Risk

What the Clinical Data Shows on Safety

The clearest safety signal from current research is the zero adverse outcome rate reported in the 2025 PMC real-world study of the FODMAP-targeting enzyme blend over four weeks. This is consistent with the generally favorable safety profile of digestive enzyme supplements in published literature.

Digestive enzymes are categorized as GRAS (Generally Recognized as Safe) by the FDA when derived from food-grade sources and used at dietary supplement doses. This applies to plant-derived enzymes (bromelain, papain) and most fungal-derived enzymes. Porcine-derived pancreatin, used in the NCT06949735 trial, has an established safety record from decades of use in pancreatic exocrine insufficiency treatment at much higher prescription doses than those used in wellness supplements.

Potential Side Effects

While serious adverse events are rare at typical supplement doses, some individuals experience:

• Mild gastrointestinal discomfort: Nausea, loose stools, or increased gas during the initial adaptation period (typically resolving within one to two weeks)
• Allergic reactions: Rare, but individuals with papaya or pineapple allergies should avoid papain- or bromelain-containing products; pork allergies are relevant for porcine-derived pancreatin products
• Interactions with anticoagulant medications: Bromelain has mild antiplatelet properties and may potentiate blood-thinning medications at high doses
• Potential mucositis at very high doses: Relevant primarily to prescription pancreatic enzyme replacement therapy (PERT) at fibrosing colonopathy doses, not typically relevant to OTC enzyme supplement doses

Are OTC Enzyme Supplements the Same as Clinical Trial Products?

This is an important practical question. The short answer is: sometimes similar, but not always identical.

Commercial products like FODZYME contain the same fructan hydrolase enzyme class studied in the 2025 PMC real-world evidence study, and the upcoming FODZYME RCT (IFFGD/Kiwi Biosciences) is specifically studying the commercial product. In this case, the consumer product and the clinical trial product are essentially the same.

However, the porcine-derived delayed-release blend in NCT06949735 is a pharmaceutical-grade formulation designed specifically for clinical investigation, and commercial equivalents may differ in enzyme source, activity levels, coating technology, and excipients.

When evaluating whether a commercial product resembles a clinical trial intervention, look for:

• Same enzyme class and source
• Comparable enzyme activity units per dose
• Same delivery formulation (delayed-release vs. standard)
• Published stability data confirming activity at time of use

Does the Evidence Support Enzyme Blends as a Replacement for Low-FODMAP Diet?

The current evidence does not support using digestive enzyme blends as a replacement for a low-FODMAP diet in IBS management. The low-FODMAP diet has the strongest evidence base among dietary interventions for IBS, with multiple RCTs showing 50–80% symptom response rates.

What the emerging enzyme blend evidence suggests is that FODMAP-targeting enzyme supplementation may serve as a complementary strategy — allowing individuals on a modified FODMAP diet to tolerate occasional high-FODMAP foods without full symptom exacerbation, or potentially reducing the strictness of ongoing FODMAP restriction. The 2026 FODZYME crossover RCT is specifically designed to test this hypothesis in a controlled setting.

Frequently Asked Questions

Can a digestive enzyme blend help with leaky gut or intestinal permeability?

A digestive enzyme blend and leaky gut relief are connected mechanistically: by improving upstream digestion of fermentable substrates, enzyme blends reduce the inflammatory substrate load reaching the colon, which may support a healthier mucosal environment. However, direct human evidence demonstrating that enzyme supplementation reduces measured intestinal permeability (via zonulin, lactulose-mannitol ratio, or FITC-dextran assays) does not yet exist in published clinical trials. The connection is biologically plausible and supported by the symptom data, but it has not been directly tested in leaky gut biomarker studies as of 2025–2026.

Is there clinical trial evidence for enzyme blends reducing bloating, gas, or abdominal pain?

Yes. The 2025 PMC study reported improvement rates of 78.0% for bloating/flatulence and 75.0% for abdominal pain in a real-world cohort using a FODMAP-targeting enzyme blend, with 72% reporting significant overall improvement on the IBS-SGA at follow-up. Multiple RCTs are currently underway, including a 300-person multicenter trial targeting completion by 2026.

Which ingredients matter most in a blend — alpha-galactosidase, beta-galactosidase, fructan hydrolase, or peptidases?

All four are clinically relevant but target different substrates. Fructan hydrolase targets fructans (wheat, garlic, onion), alpha-galactosidase targets galacto-oligosaccharides (legumes), beta-galactosidase/lactase targets lactose (dairy), and prolyl-endopeptidase targets gluten peptides. For individuals whose leaky gut symptoms appear after meals containing these specific trigger foods, choosing a blend that includes the appropriate targeting enzyme is more important than selecting based on brand alone.

Are these products being studied specifically for leaky gut syndrome?

Current registered clinical trials are primarily studying outcomes related to IBS symptoms — bloating, gas, abdominal pain, and overall digestive symptom scores — rather than intestinal permeability biomarkers directly. The broader clinical category of "leaky gut" overlaps significantly with IBS-related complaints, and the symptom outcomes being studied are directly relevant. As the field matures, future trials may incorporate permeability biomarkers as primary or secondary endpoints.

How long does it take to see results from a digestive enzyme blend?

Based on the 2025 PMC study's four-week assessment and the trial durations of studies in this space, clinically meaningful symptom improvement may be observable within two to four weeks of consistent use. For FODMAP-specific enzymes taken with meals, some individuals report symptom improvement from the first few doses — because the mechanism (preventing fermentation substrate from reaching the colon) is acute rather than requiring a cumulative biological effect.

Are digestive enzyme supplements safe, and what side effects have been reported?

The 2025 PMC study reported zero adverse outcomes over four weeks in its study population. The broader safety profile of digestive enzyme supplements at OTC doses is favorable, with mild GI adjustment symptoms (temporary gas, loose stools) as the most commonly reported issues. Individuals with allergies to pork, papaya, or pineapple should select enzyme sources accordingly.

Are over-the-counter enzyme supplements the same as the products used in clinical trials?

In some cases, yes — particularly for FODZYME's fructan hydrolase product, which is both a commercial product and the intervention being studied in the Kiwi Biosciences-sponsored RCT. For pharmaceutical-grade delayed-release formulations like the one in NCT06949735, commercial equivalents may vary in delivery technology and potency.

Does the evidence support enzyme blends as a replacement for a low-FODMAP diet?

No. The current evidence supports enzyme blends as a complementary tool, not a replacement. The low-FODMAP diet remains the most evidence-backed dietary intervention for IBS. Enzyme blends may reduce the strictness of FODMAP restriction needed to achieve symptom control, which is a meaningful clinical benefit, but this hypothesis is still being tested in the ongoing 2026 RCTs.

Support Your Gut System, Reduce Bloating and Feel Lighter Within Minutes.

Try our new organic debloat + digest drops risk free

Verdant Debloat + Digest Drops - Feel Lighter in Minutes

Shop Organic Debloat + Digest Drops

The Bottom Line

The evidence base for using a digestive enzyme blend for leaky gut is at an inflection point in 2025–2026. We are past the point of theoretical interest and into the early stages of rigorous clinical investigation, with multiple registered trials providing a clear roadmap for where the science is heading.

Here is what we know with confidence:

• A FODMAP-targeting digestive enzyme blend produced 78% improvement in bloating/flatulence and 75% improvement in abdominal pain in the first major real-world human study, with zero reported adverse outcomes
• The 2024 Frontiers in Nutrition ileostomy study demonstrated objective, measurable improvement in small intestinal carbohydrate digestion with enzyme blend supplementation
• Multiple RCTs — including a 24-person phase 2 crossover trial and a 300-person multicenter trial — are either completed or recruiting, with results expected to reshape clinical guidance
• The 2025 PMC authors themselves called for a prospective randomized controlled trial, acknowledging that the real-world evidence, while compelling, requires confirmation

Here is what remains to be proven:

• Whether enzyme blends directly reduce intestinal permeability biomarkers in humans
• Whether the symptom improvements observed in real-world data hold up under rigorous double-blind, placebo-controlled conditions
• Whether long-term enzyme use provides sustained benefits or loses effect over time
• The optimal enzyme composition, dose, and formulation type for individuals with different symptom profiles

For individuals currently suffering from digestive symptoms associated with leaky gut — bloating, gas, abdominal pain, post-meal discomfort — the current evidence is sufficient to consider a trial of a well-formulated, activity-tested digestive enzyme blend as part of a broader gut health strategy. The safety profile is favorable, the symptom data is encouraging, and the mechanistic rationale is sound.

For clinicians, the message is that this is a rapidly evolving evidence base. The dismissal of enzyme supplementation as unproven is increasingly difficult to sustain given the quality and consistency of the emerging data, while the endorsement of enzyme blends as established therapy for leaky gut would still be premature without the confirmatory RCT data that is currently being generated.

The clinical trial landscape for digestive enzyme blend for leaky gut is active, growing, and producing data that will likely inform clinical recommendations within the next two to three years. The science is catching up to what many patients and clinicians have observed empirically for years: supporting complete digestion with targeted enzyme supplementation can meaningfully improve gastrointestinal symptom burden, and that improvement matters for the health of the gut barrier itself.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning any supplement regimen, particularly if you have diagnosed gastrointestinal conditions, take prescription medications, or have known enzyme or food allergies.

References

[1] PMC. (2025). FODMAP-targeting digestive enzyme blend and IBS symptom outcomes: Real-world evidence. PMC Article PMC13018943. https://pmc.ncbi.nlm.nih.gov/articles/PMC13018943/

[2] MedPath. (2025). NCT06949735: Digestive enzyme supplementation postprandial responses high macronutrient meal — Phase 2 clinical trial. https://trial.medpath.com/clinical-trial/02c5437b7e174a49/nct06949735-digestive-enzyme-supplementation-postprandial-responses-high-macronutrient-meal

[3] MedPath. (2026). Clinical study on a blend of digestive enzymes and extracts for bloating in adults. MedPath trial listing.

[5] PMC. (2024). Review: Leaky gut and ingredients that may help treat it. PMC.

[6] Clinical trial registry. (2026). NCT07465562: Multicenter randomized controlled trial of alpha-galactosidase, beta-galactosidase, and prolyl-endopeptidase for food-related abdominal bloating. Target enrollment: 300.

[7] IFFGD. (2026). Randomized, double-blind, placebo-controlled crossover study of FODMAP-targeting digestive enzyme blend for bloating. Sponsored by Kiwi Biosciences (FODZYME).

[11] Frontiers in Nutrition. (2024). Acute physiological effects of a digestive enzyme blend on macromolecule digestion. Frontiers in Nutrition, 11, 1357803. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1357803/full